Table II. Duration of prophase in Indian muntjac cells treated with topo II inhibitors.

Treatment	None	SB203580 (50 μM/1 h)
None	55 ± 13 (16)	49 ± 16 (5)
Aclarubicin (0.75–1 μM)	300 ± 141 (3)	57 ± 4 (6)
ICRF-193 (4 μM)	384 ± 187 (3)	101 ± 35 (2)

Duration of prophase (min) in Indian muntjac cells treated with aclarubicin or ICRF-193 in the absence or presence of SB203580. Note that inhibiting p38 significantly reduces the duration of prophase in cells treated with topo II inhibitors. The data in A and B represent the average ± SD; the number of cells followed is shown in parentheses.